Penumbra (NYSE:PEN – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Canaccord Genuity Group in a research note issued on Tuesday, Benzinga reports. They currently have a $374.00 price target on the stock. Canaccord Genuity Group‘s price objective indicates a potential upside of 16.75% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. Zacks Research upgraded shares of Penumbra from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Weiss Ratings upgraded shares of Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, October 30th. Three research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. Based on data from MarketBeat.com, Penumbra currently has a consensus rating of “Hold” and an average target price of $367.07.
Read Our Latest Analysis on PEN
Penumbra Stock Down 0.1%
Penumbra stock traded down $0.29 on Tuesday, hitting $320.33. 21,573 shares of the stock traded hands, compared to its average volume of 571,588. Penumbra has a 1 year low of $276.01 and a 1 year high of $362.41. The firm has a market cap of $12.62 billion, a P/E ratio of 80.69 and a beta of 0.71. The company has a current ratio of 5.89, a quick ratio of 3.92 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $320.15 and its 200 day simple moving average is $325.89.
Penumbra (NYSE:PEN – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $1.07 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.13). Penumbra had a return on equity of 10.39% and a net margin of 10.06%. The business had revenue of $410.15 million during the quarter, compared to analysts’ expectations of $401.41 million. During the same period in the prior year, the company earned $0.97 earnings per share. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Penumbra will post 4.96 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its holdings in Penumbra by 7.1% in the third quarter. Parallel Advisors LLC now owns 514 shares of the company’s stock worth $164,000 after purchasing an additional 34 shares during the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Penumbra by 48.7% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 116 shares of the company’s stock worth $37,000 after purchasing an additional 38 shares during the period. North Dakota State Investment Board raised its stake in Penumbra by 3.5% during the 3rd quarter. North Dakota State Investment Board now owns 1,166 shares of the company’s stock valued at $371,000 after buying an additional 39 shares during the last quarter. Oregon Public Employees Retirement Fund raised its stake in Penumbra by 0.6% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 8,130 shares of the company’s stock valued at $2,588,000 after buying an additional 49 shares during the last quarter. Finally, Bessemer Group Inc. raised its stake in Penumbra by 37.8% during the 3rd quarter. Bessemer Group Inc. now owns 237 shares of the company’s stock valued at $76,000 after buying an additional 65 shares during the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.
About Penumbra
Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.
Further Reading
- Five stocks we like better than Penumbra
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
